New publication: LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function
Joshi Alumkal, M.D., is a physician-scientist who focuses on making fundamental discoveries about what drives lethal human prostate cancer with the goal of developing novel treatments that will improve patient outcomes.
The Alumkal laboratory focuses on identifying mechanisms by which prostate cancer progresses to the lethal form of the disease that is resistant to male hormone-lowering therapies. We believe molecular methods can be used to understand this process. Our goal is to apply insights from the lab to clinical trials for patients.